Rampart IC Secures Series B Financing to Fuel Strategic Growth and Expand Access to Radiation Safety Solutions
Rampart IC News
Birmingham, Alabama – Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was led by Vensana Capital, a leading venture capital firm specializing in transformative healthcare innovation.
This latest investment will support accelerated global commercialization of Rampart’s disruptive technologies through strategic acquisitions, continued product development and further clinical expansion into new service lines. Rampart’s radiation protection portfolio is transforming how healthcare professionals are protected during procedures involving ionizing radiation. Uniquely designed to provide superior whole-body protection, Rampart’s solutions enable clinical staff to confidently remove lead aprons that are often linked to orthopedic injuries.
“We’re thrilled to have Vensana Capital join us as a strategic partner in our next phase of growth,” said Tom Livingston, CEO of Rampart IC. “This financing not only validates the strong clinical need for our technology but also enables us to scale our operations and bring our innovations to more hospitals and interventional suites around the world. With Vensana’s deep sector expertise and shared commitment to patient and provider safety, we are well-positioned to redefine standards in interventional care.”
A recent survey conducted by the Society of Cardiovascular Angiography and Interventions (SCAI) found that over 60% of interventional workers reported orthopedic injuries due to prolonged use of lead aprons, with spine injuries being the most common. Additionally, 17% of respondents admitted to limiting their time in the lab to reduce their radiation exposure, a significant increase from previous surveys.
“Rampart is confronting one of the most urgent and overlooked challenges in interventional care – protecting healthcare professionals from harmful radiation exposure and the long-term orthopedic consequences of legacy shielding methods,” said Mike Kramer and Kirk Nielsen of Vensana Capital. “We’re proud to back a team that’s not only driving breakthrough innovation but also setting the bar for clinical rigor through its commitment to peer-reviewed research and published clinical trials. We are excited to support their vision of interventional suites without lead.”
About Rampart IC
Rampart IC is a Birmingham, Alabama-based medical device company whose radiation shielding solutions provide team protection in the interventional suite without the need to wear traditional lead aprons, which can cause orthopedic issues for some team members. Available directly and through distribution partnerships, Rampart’s solutions are implemented in cath labs and other interventional suites worldwide.
About Vensana Capital
Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Founded in 2019, Vensana has approximately $1 billion in capital under management and is actively investing in development and commercial stage companies across the medtech sector, including medical devices, data science-oriented solutions, life science tools & diagnostics, and tech-enabled services. Vensana’s investment team has a history of successfully partnering with entrepreneurs behind industry-leading companies, including Artelon, Cameron Health, CardiAQ, Cartiva, CV Ingenuity, CVRx, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical. Learn more at www.vensanacap.com.
Find More:
Cardiovascular Ambulatory Surgery Centers (ASCs) Topic Center
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
Peripheral Artery Disease Topic Center
